|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- NHS Trusts (England) - Chief Executive
|
| Title: |
|
Neutralising monoclonal antibody and intravenous antiviral treatments for patients in hospital with COVID-19 infection
|
| Broadcast content: |
|
The published policy providing access to neutralising monoclonal antibodies (nMABs) for hospitalised patients with COVID infection has been updated to reflect the RECOVERY trial’s announcement of a new sotrovimab arm for patients hospitalised due to COVID and to include a new treatment option of intravenous antiviral therapy (remdesivir (Veklury)) for patients with hospital onset COVID infection. PCR positive antibody seronegative patients admitted to hospital DUE to COVID infection can continue to be offered the combination monoclonal antibody casirivimab and imdevimab (Ronapreve) only where infection with a non-Omicron variant has been confirmed through genotyping. Clinicians are encouraged to consider entering all other patients hospitalised due to COVID into the RECOVERY trial, which is studying sotrovimab vs standard of care in this cohort. Genotyping of all inpatients is recommended to assist in treatment decisions and to support wider surveillance.
|
| Additional information: |
|
This alert does not need to be cascaded to Primary Care
|